Edrophonium: Short-Acting Acetylcholinesterase Inhibitor and Historical Myasthenia Testing

Medical pharmacology review updated 10 November 2026. Educational material; local labeling, emergency protocols and clinical toxicology guidance take precedence in individual patient care.

Overview and major correction

Edrophonium chloride is a synthetic short-acting, reversible acetylcholinesterase inhibitor. It is a quaternary ammonium compound; it is not ‘tetraethylammonium chloridate’, which is a different chemical entity. By transiently increasing acetylcholine at cholinergic synapses it can briefly improve neuromuscular transmission in myasthenia gravis. However, its historical bedside Tensilon test is no longer routinely recommended and the drug is unavailable in the United States [1–3].

Molecular mechanism

Edrophonium binds reversibly and noncovalently to acetylcholinesterase, slowing hydrolysis of acetylcholine into choline and acetate. Increased acetylcholine improves signaling at remaining functional muscle-type nicotinic receptors in myasthenia gravis, while muscarinic receptor stimulation can cause bradycardia, secretion, sweating, bronchospasm or diarrhea. Because edrophonium is charged, it crosses the blood–brain barrier poorly. Its effect begins rapidly after IV administration but is brief [1].

Historical Tensilon test and limitations

Traditionally, objectively measurable ptosis or other weakness was reassessed immediately after cautious administration, with improvement interpreted as supporting neuromuscular-junction dysfunction. This response is not fully specific, is vulnerable to observer bias and may be hard to distinguish from unrelated fluctuations. The 2025 Association of British Neurologists guidance states that edrophonium testing is no longer recommended because of potentially significant complications, including bradycardia and vomiting. Presenting it as the contemporary diagnostic gold standard would be inaccurate [2,3].

Modern evaluation of suspected myasthenia gravis

Current diagnostic workup begins with fatigable weakness and examination, followed by acetylcholine-receptor antibodies, MuSK or other relevant antibodies and specialized electrophysiology such as repetitive nerve stimulation or single-fiber EMG. The ice-pack test can support assessment of ptosis. Specialist evaluation is needed for potentially life-threatening bulbar or respiratory weakness. A negative antibody test does not exclude all MG, and an edrophonium response should not be used as sole confirmation [2,3].

Safety and monitoring

Potential severe effects include profound bradycardia, AV conduction problems, hypotension, bronchospasm and cholinergic toxicity. If pharmacologic testing is attempted in a jurisdiction that still uses edrophonium, it requires experienced clinicians, monitoring, resuscitation equipment and atropine availability; routine unsupervised diagnostic administration is unacceptable. Cardiac conduction disease and asthma create particular hazards [1,3].

Educational comparison

Edrophonium illustrates rapidly reversible acetylcholinesterase inhibition. Pyridostigmine is a longer-acting agent for symptomatic myasthenia treatment; neostigmine is used in specific neuromuscular blockade reversal contexts. Neither should be confused with edrophonium’s historically short diagnostic effect or with immunomodulatory treatments for autoimmune MG [1,2].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. Association of British Neurologists. Autoimmune myasthenia gravis management guidelines: 2025 update. 2025. Available from: https://www.euroimmun.pl/wp-content/uploads/2026/01/British-Neurologists-Miastenia-Gravis-2025.pdf
  3. Merck Manual Professional Edition. Myasthenia gravis: diagnosis and treatment. Available from: https://www.merckmanuals.com/professional/neurologic-disorders/peripheral-nervous-system-and-motor-unit-disorders/myasthenia-gravis
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *